$Glycogen synthase kinase 3 beta inhibitor SB216763 improves Kir2.1 expression after myocardia infraction in rats$

Glycogen synthase kinase 3 beta inhibitor SB216763 improves Kir2.1 expression after myocardia infraction in rats

Background Abnormal ion channel currents caused by myocardial electrical remodeling is one of the main causes of malignant arrhythmias. Glycogen synthase kinase 3β (GSK-3β) is the main therapeutic target following ischemia as it regulates nerve cell channels. However, few studies have investigated i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of interventional cardiac electrophysiology 2022-03, Vol.63 (2), p.239-248
Hauptverfasser:	Chang, Cheng, Wang, Shu-Hui, Xu, Li-Na, Su, Xue-Ling, Zeng, Yi-Fan, Wang, Peng, Zhang, Li-Rong, Han, Sheng-Na
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Calcium-binding protein Cardiology Echocardiography EKG Electrocardiography Enzyme inhibitors Gene expression Glycogen Glycogen synthase kinase 3 Glycogen Synthase Kinase 3 beta Glycogens Heart Humans Hypoxia Indoles - pharmacology Ion channels Ischemia Kinases L-Lactate dehydrogenase Lactate dehydrogenase Lactic acid Maleimides - pharmacology Medicine Medicine & Public Health mRNA Myocardial infarction Myocardium Potassium channels (inwardly-rectifying) Protein expression Proteins Rats Therapeutic targets Troponin Troponin I Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!